Chronic neutropenia
X4 Pharma Halves Workforce in Second Round of 2025 Layoffs
X4 Pharmaceuticals; layoffs; restructuring; chronic neutropenia; mavorixafor; management changes; biotech
X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion
X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring